{"product_id":"cancer-medical-consultation-en","title":"Cancer Consultation","description":"\u003ch1\u003eCancer Medical Consultation\u003c\/h1\u003e\n\u003ch3\u003ePersonalized Treatment Analysis · Second Opinion · Cancer Immunotherapy in Japan\u003c\/h3\u003e\n\u003cp\u003eCancer is not a single disease. Even among patients with the same type of cancer, tumor characteristics, genetic alterations, immune status, disease progression, and response to treatment can vary considerably.\u003c\/p\u003e\n\u003cp\u003eWe therefore believe that the first step toward a more personalized treatment strategy is to understand each patient’s condition as comprehensively as possible.\u003c\/p\u003e\n\u003cp\u003eDuring the consultation, we review the medical information you provide, including:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImaging Studies\u003c\/strong\u003e\u003cbr\u003eCT, MRI, PET-CT, and other relevant imaging\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePathology Reports\u003c\/strong\u003e\u003cbr\u003eCancer type, stage, histology, and relevant pathological features\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBlood Tests\u003c\/strong\u003e\u003cbr\u003eBlood counts, liver and kidney function, inflammatory markers, tumor markers, and other relevant results\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMolecular and Genetic Testing\u003c\/strong\u003e\u003cbr\u003eTumor genomic profiling, molecular biomarkers, and other available test results\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCurrent and Previous Treatments\u003c\/strong\u003e\u003cbr\u003eSurgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, and other treatments\u003c\/p\u003e\n\u003cp\u003eWe integrate these findings with your treatment history and current condition, and assess potential next steps from the perspectives of cancer immunology and personalized medicine.\u003c\/p\u003e\n\u003cp\u003eWhether you have been newly diagnosed, are currently undergoing treatment, have recurrent or metastatic disease, or have completed primary treatment and wish to explore strategies for reducing the risk of recurrence, the consultation is tailored to your individual situation.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eMore Than Choosing a Treatment\u003c\/h1\u003e\n\u003cp\u003eCancer treatment is becoming increasingly personalized.\u003c\/p\u003e\n\u003cp\u003eCancer cells can continue to evolve during disease progression and treatment. Different cells within the same tumor may also have different molecular and immunological characteristics.\u003c\/p\u003e\n\u003cp\u003eFor this reason, treatment decisions should not be based solely on the name or type of cancer.\u003c\/p\u003e\n\u003cp\u003eOur assessment may take into consideration:\u003c\/p\u003e\n\u003ch3\u003eCancer type and stage\u003c\/h3\u003e\n\u003ch3\u003eMolecular and genetic characteristics of the tumor\u003c\/h3\u003e\n\u003ch3\u003eImmune status\u003c\/h3\u003e\n\u003ch3\u003ePrevious and current treatments\u003c\/h3\u003e\n\u003ch3\u003eOverall physical condition and organ function\u003c\/h3\u003e\n\u003ch3\u003eTreatment response and disease progression\u003c\/h3\u003e\n\u003cp\u003eBased on this information, we can assess the potential role of different cancer immune-cell therapies and whether they may be considered alongside existing standard treatments.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003ePersonalized Cancer Immune-Cell Therapy\u003c\/h1\u003e\n\u003cp\u003eMeiko CIT Clinic in Tokyo focuses on personalized cancer immune-cell therapy.\u003c\/p\u003e\n\u003cp\u003eDepending on the individual characteristics of the patient and the cancer, potential treatment approaches may include:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDendritic Cell Vaccine Therapy\u003c\/strong\u003e\u003cbr\u003eDendritic cells present cancer-associated antigens to help guide T cells in recognizing tumor cells.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePersonalized Neoantigen Dendritic Cell Vaccine\u003c\/strong\u003e\u003cbr\u003eTumor-specific alterations are analyzed to identify patient-specific neoantigens that may serve as more individualized immune targets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eActivated T Cell Therapy\u003c\/strong\u003e\u003cbr\u003eThe patient’s own T lymphocytes are collected, cultured, expanded and activated outside the body before being reinfused to strengthen cellular immune activity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNK Cell Therapy\u003c\/strong\u003e\u003cbr\u003eNatural killer cells are cultured and activated to support the innate immune system’s ability to recognize and attack abnormal cells.\u003c\/p\u003e\n\u003cp\u003eThe aim is not simply to use as many different immune cells as possible.\u003c\/p\u003e\n\u003ch3\u003eThe important question is which immune strategy is most appropriate for the individual patient and cancer.\u003c\/h3\u003e\n\u003chr\u003e\n\u003ch1\u003eWhy Is an Individual Assessment Important?\u003c\/h1\u003e\n\u003cp\u003eOne of the major challenges of cancer is its ability to change over time.\u003c\/p\u003e\n\u003cp\u003eTumors can contain considerable genetic and epigenetic heterogeneity. During natural disease progression and under the selective pressure of treatment, some cancer-cell populations may acquire characteristics that allow them to survive or become resistant.\u003c\/p\u003e\n\u003cp\u003eA treatment that was initially effective may therefore not necessarily control the disease indefinitely.\u003c\/p\u003e\n\u003cp\u003eSimilarly, even when imaging shows significant tumor regression or no detectable disease, medical imaging has limits of detection and cannot by itself exclude the presence of all microscopic or residual cancer cells.\u003c\/p\u003e\n\u003cp\u003eThis is one reason why ongoing surveillance and reassessment can remain important even after a good treatment response.\u003c\/p\u003e\n\u003ch3\u003eCancer treatment is not always a single decision—it is an evolving strategy that may need to change as the disease changes.\u003c\/h3\u003e\n\u003chr\u003e\n\u003ch1\u003eReducing the Risk of Cancer Recurrence\u003c\/h1\u003e\n\u003cp\u003eFor patients who have completed their primary cancer treatment and currently have no detectable disease, the focus of consultation can be different.\u003c\/p\u003e\n\u003cp\u003eRather than treating measurable tumors, we may discuss longer-term strategies involving:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCancer surveillance and appropriate follow-up\u003c\/strong\u003e\u003cbr\u003e\u003cstrong\u003eManagement of modifiable health and recurrence risk factors\u003c\/strong\u003e\u003cbr\u003e\u003cstrong\u003eImmune health and immune surveillance\u003c\/strong\u003e\u003cbr\u003e\u003cstrong\u003eLifestyle, nutrition and recovery after cancer treatment\u003c\/strong\u003e\u003cbr\u003e\u003cstrong\u003eWhether preventive immune-cell therapy is appropriate to consider\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eT cells and NK cells play important roles in normal immune surveillance of abnormal cells. For selected individuals, we can discuss the rationale, limitations and available evidence for preventive immune-cell approaches as part of a broader long-term management strategy.\u003c\/p\u003e\n\u003cp\u003ePreventive immune-cell therapy cannot guarantee that cancer will not recur and should not replace evidence-based cancer surveillance, screening or standard follow-up care.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eOur Treatment Philosophy\u003c\/h1\u003e\n\u003cp\u003eOur aim is not to replace conventional cancer treatment with immune-cell therapy.\u003c\/p\u003e\n\u003cp\u003eSurgery, chemotherapy, radiotherapy, targeted therapies, immune checkpoint inhibitors and cellular immunotherapies each work through different mechanisms and have different indications.\u003c\/p\u003e\n\u003cp\u003eFor some patients, standard treatment remains the most appropriate option. For others, it may be reasonable to explore whether personalized immune-cell therapy could complement their existing treatment strategy.\u003c\/p\u003e\n\u003cp\u003eWe therefore focus on understanding the individual patient first, rather than recommending the same treatment to everyone.\u003c\/p\u003e\n\u003cp\u003eIn addition to cancer treatment itself, we also consider nutrition, lifestyle, physical recovery and long-term health management to support quality of life during and after treatment.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eWho Is This Consultation For?\u003c\/h1\u003e\n\u003cp\u003eThis consultation may be suitable for:\u003c\/p\u003e\n\u003cp\u003ePatients who have recently been diagnosed with cancer and wish to better understand their treatment options\u003c\/p\u003e\n\u003cp\u003ePatients currently undergoing cancer treatment who wish to explore additional treatment strategies\u003c\/p\u003e\n\u003cp\u003ePatients whose cancer has not responded adequately to treatment or has developed treatment resistance\u003c\/p\u003e\n\u003cp\u003ePatients with recurrent or metastatic cancer who wish to reassess their treatment strategy\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCancer survivors who have completed primary treatment and wish to explore strategies for reducing recurrence risk and supporting long-term immune surveillance\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients currently in remission who wish to develop a longer-term health and immune-management strategy\u003c\/p\u003e\n\u003cp\u003ePatients interested in cancer immune-cell therapies available in Japan\u003c\/p\u003e\n\u003cp\u003ePatients or families seeking a Second Opinion\u003c\/p\u003e\n\u003chr\u003e\n\u003ch1\u003eWhat Happens After Purchase?\u003c\/h1\u003e\n\u003cp\u003eAfter purchasing the consultation, a member of our team will contact you and send you a \u003cstrong\u003eHealth and Medical History Form\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003ePlease complete the form and return it together with your most recent and relevant medical records, including imaging, pathology reports, blood-test results, genetic or molecular testing, and details of your current treatment where available.\u003c\/p\u003e\n\u003cp\u003eOnce we have received the complete information, your records will be reviewed and analyzed.\u003c\/p\u003e\n\u003ch3\u003eYou may choose one of the following:\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e1 | Personalized Written Analysis\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA written review of the key aspects of your medical information, with personalized considerations regarding cancer immunotherapy, treatment strategy and potential treatment options in Japan.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOR\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2 | 30-Minute Online Video Consultation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA 30-minute online consultation with \u003cstrong\u003eDr. Queenie Lam\u003c\/strong\u003e, during which your medical information, current treatment and potential next steps can be discussed.\u003c\/p\u003e\n\u003cp\u003eThe selected written analysis or video consultation will be arranged \u003cstrong\u003ewithin five working days after we have received all necessary medical information\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eThis consultation may be used once within one year from the date of purchase.\u003c\/h3\u003e\n\u003chr\u003e\n\u003ch3\u003eImportant Information\u003c\/h3\u003e\n\u003cp\u003eThis consultation provides professional analysis and information regarding cancer immunology, treatment options and medical treatment in Japan based on the records supplied by the patient.\u003c\/p\u003e\n\u003cp\u003eFinal diagnosis and treatment decisions should be made by the appropriate treating physician based on the patient’s complete clinical condition and, where required, an in-person medical assessment.\u003c\/p\u003e\n\u003cp\u003eEvery cancer is different. Cancer type, stage, molecular characteristics, overall health and response to treatment vary between individuals, and no particular treatment outcome can be guaranteed.\u003c\/p\u003e\n\u003cp\u003eThis service does not replace emergency medical care or medically necessary standard cancer treatment.\u003c\/p\u003e","brand":"株式会社ケアリングフロムジャパン Caring from Japan","offers":[{"title":"Default Title","offer_id":42974075060406,"sku":null,"price":5463.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0578\/4915\/1670\/files\/EarthyLayoutMedicalCenterInstagramPost_75a4e0a8-4418-4e85-9338-a60ca46047da.png?v=1713183452","url":"https:\/\/caringfromjapan.com\/en-us\/products\/cancer-medical-consultation-en","provider":"株式会社ケアリングフロムジャパン Caring from Japan ","version":"1.0","type":"link"}